Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04256603 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI
A Phase 4 study, sponsored by MetroHealth Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT04256603 is a Phase 4 study that has completed, run by MetroHealth Medical Center. The registered enrollment target is 27 participants.
The verdict
NCT04256603, a Phase 4 study, has completed, sponsored by MetroHealth Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
Neuropathic pain is a common complaint in those with spinal cord injury (SCI) that has a significant negative effect on quality of life. Efficacy of various treatments, however, remains controversial. There is evidence to support that gabapentin and pregabalin have some benefit in reducing neuropathic pain. Gabapentin is effective in the management of symptoms and concerns related to SCI including motor recovery, spasticity, and mood among others. This makes gabapentin an important pharmacologic intervention, which compels providers to define treatment guidelines related to its use. One aspect of which should relate to the timing of initiation of therapy. The goal of this study is to determine whether timing of initiation of treatment with gabapentin will decrease prevalence and intensity of neuropathic pain.
Interventions
- DRUG Gabapentin
- OTHER No gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04256603
The ClinicalTrials.gov registry entry for NCT04256603 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MetroHealth Medical Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gabapentin is the first listed.
NCT04256603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04256603 about?
NCT04256603 is a clinical study titled "Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI". Neuropathic pain is a common complaint in those with spinal cord injury (SCI) that has a significant negative effect on quality of life. Efficacy of various treatments, however, remains controversial. There is evidence to support that gabapentin and pregabalin have some benefit in reducing neuropath...
What is the current status of trial NCT04256603?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2019-08-01. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT04256603?
The interventions under investigation include: Gabapentin (DRUG), No gabapentin (OTHER).
Who is sponsoring clinical trial NCT04256603?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.